Private Equity Looking for Interns - Gilde Healthcare

Private Equity Looking for Interns

22 augustus 2018

Gilde Healthcare Services, a lower mid-market buy-out fund focused on Benelux and Germany, is looking for a student intern that is able to support the investment team with its activities.

Given the compact investment team, the intern will have the opportunity to take an integral role in a deal team. The intern will have the opportunity to engage in many parts of the investment process, with an emphasis on the deal origination phase. Strong analytical skills, an excellent track record and an entrepreneurial spirit are therefore required. We assume fluency in English and either Dutch or German. A previous internship in corporate finance, strategy consultancy or private equity is appreciated. You will work 3 (or more) months in the city of Utrecht as member of our investment team.

More information on Gilde Healthcare: gildehealthcare.com
More information on this position: Mr. T. Klein Robbenhaar, robbenhaar@gildehealthcare.com
When interested, please send your resume and concise motivational email and we will be in contact with you.

 

 

Meer nieuws

Gilde Healthcare lanceert Climate Solutions fonds en haalt €250 mln op

Met commitments van internationale pensioenfondsen, banken, fund-of-funds, endowments en family offices realiseert Gilde Healthcare een eerste closing van €250 miljoen Uitbreiding naar Climate Solutions bouwt voort op Gilde Healthcare’s track-record in impactvol investeren en rapportage...
18 februari 2026

Gilde Healthcare Company Big Health Secures Funding to Accelerate Adoption of Digital Mental Health Treatments

New investment fuels expansion as leading health systems adopt evidence-based digital care, driven by new billing codes and strong demand for proven mental health solutions. Big Health, a leading developer of digital treatments for the...
12 februari 2026

Gilde Healthcare company SpyGlass Pharma announces pricing of initial public offering at NASDAQ

SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per...
6 februari 2026